ADVOCATE. CONNECT. INNOVATE.

CLSA Wire

Independent Payment Advisory Board (IPAB) Repeal Passes the House
Facebook
Twitter
LinkedIn

Nov. 27, 2017

The Independent Payment Advisory Board (IPAB) is a controversial advisory board enacted as part of the Affordable Care Act in 2010, which threatens seniors’ care and could harm biomedical innovation by reducing incentives for investment in new research and product development. CLSA opposed the establishment of the IPAB since its inception and has called for its repeal ever since.

On Nov. 2, the House passed H.R. 849, the Protecting Seniors’ Access to Medicare Act, legislation to repeal the IPAB, by a vote of 307-111, with a total of 76 Democrats voting in favor of repeal. Click here to view CLSA’s press release applauding the House vote.

For the past few months, with all the discussion of healthcare reform at the top of legislators’ minds, CLSA’s DC office actively engaged members of the California Delegation offices to express our support for H.R. 849. Not only did CLSA issue a letter of endorsement of H.R. 849, we also joined over 760 other stakeholders to call for an immediate repeal of IPAB. This past April, an op-ed authored by CLSA’s President & CEO, Sara Radcliffe, was published by the San Jose Mercury News, urging repeal of IPAB.

The California Delegation overwhelmingly supported the measure, voting 30-20 for passage. Notably, the yea count included 17 Democrats from our delegation, representing almost 23% of the total number of Democrats who voted for the bill. We are proud to report that five out of our six freshman delegation members voted in support of the bill (Reps. Barragán, Carbajal, Correa, Gomez and Panetta). Three members of the delegation did not vote (Reps. Nunes, Peters and Speier). Rep. Scott Peters was unable to vote due to international travel on official business; he would have voted yes had he been present, and will be submitting a statement for the record indicating his views.

The bill now must be considered by the Senate for a vote, however, a schedule for action has not been announced.

On behalf of California’s life sciences innovators, a sector with over 3,000 firms employing nearly 300,000 people, California Life Sciences Association joins the rest of the biomedical innovation ecosystem in supporting the repeal of IPAB, which would have harmful and long-lasting effects on medical innovation. Visit CLSA’s Digital Action Center to send a letter to your Senator, urging repeal of IPAB. Questions? Please contact Adam Lotspike, CLSA’s Associate Director of Federal Government Relations (alotspike@califesciences.org).